Your browser is not supported.

To view this content, please use one of the following browsers:

  • Microsoft Edge
  • Chrome
  • Safari
  • Home
  • Resources
  • Articles
  • SGLT2 inhibitors superior vs. DPP4 inhibitors, findings from a meta-analysis

SGLT2 inhibitors superior vs. DPP4 inhibitors, findings from a meta-analysis

SGLT2 inhibitors superior vs. DPP4 inhibitors, findings from a meta-analysis

Researchers carried out a meta-analysis on 30 studies that compared the effects of SGLT2 (sodium glucose co-transporter 2) inhibitors vs. DPP4 (dipeptidyl peptidase 4) inhibitors in type 2 diabetes, and found superiority of SGLT2 inhibitors over DPP4 inhibitors across a broad spectrum of cardiovascular (CV) outcomes and metabolic risk factors, including

Reduced cardiovascular risks of

o Stroke (risk ratio [RR]=0.80; 95% confidence interval [CI], 0.76-0.84);

o Myocardial Infarction (RR=0.85; 95% CI, 0.81-0.89);

o Heart Failure (RR=0.58; 95% CI, 0.54-0.62);

o CV mortality (RR=0.55; 95% CI, 0.51-0.60);

o All-cause mortality (RR=0.60; 95% CI, 0.57-0.63); and

Lower levels of

o HbA1c (weighted mean difference [WMD]=-0.07%; 95% CI, -0.13 to -0.01; WMD=-1.90 mmol/mol; 95% CI, -3.18 to -0.61);

o Fasting Plasma Glucose (WMD=-7.39mg/dL; 95% CI, -9.73 to -5.06)

o Body weight (WMD=-2.16 kg; 95% CI, -2.42 to -1.90);

o Other cardiometabolic risk factors such as body-mass index, systolic and diastolic blood pressure.

These findings provide another basis for the selection of second-line agents in treating type 2 diabetes.

Prescribing information for Invokana (canagliflozin)

T2DM Logo

Napp brings you recent and clinically relevant publications in the evolving field of Type 2 diabetes recommended by an international panel of specialists.

Editorial Board

Image
Dr. Salvatore A. De Cosmo's image

Dr. Salvatore A. De Cosmo

Head of Unit of Internal Medicine and Endocrinology, Scientific Institute “Casa Sollievo della Sofferenza” San Giovanni, Rotondo, Italy
,
Image
Dr. Juan José Gorgojo Martínez's image

Dr. Juan José Gorgojo Martínez

Head of Department of Endocrinology and Nutrition, University Hospital Fundación, Alcorcon, Madrid, Spain
,
Image
Dr. Patrick Holmes' image

Dr. Patrick Holmes

General Practitioner, St. George's Medical Practice, Darlington, UK

Editorial Board

Image
Dr. Salvatore A. De Cosmo's image

Dr. Salvatore A. De Cosmo

Head of Unit of Internal Medicine and Endocrinology, Scientific Institute “Casa Sollievo della Sofferenza” San Giovanni, Rotondo, Italy
Image
Dr. Juan José Gorgojo Martínez's image

Dr. Juan José Gorgojo Martínez

Head of Department of Endocrinology and Nutrition, University Hospital Fundación, Alcorcon, Madrid, Spain
Image
Dr. Patrick Holmes' image

Dr. Patrick Holmes

General Practitioner, St. George's Medical Practice, Darlington, UK

Publication under Spotlight

Comparison of cardiovascular outcomes and cardiometabolic risk factors between patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors: a meta-analysis

 

Eur J Prev Cardiol
2022 ;28 (16) : 1840-1849

 

Authors: Siwen Wang, Ting Wu, Zhihong Zuo, Ping Jin, Xuan Luo and Meichun Deng

READ MORE